Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – ...

Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the ...

NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...

Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its ...

Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company ...

Despite reporting positive topline results from the Phase 3 VERITAC-2 trial and presenting promising data for its neuroscience program, the clinical-stage biotechnology firm’s decision to re ...

Reported positive topline data for VERITAC-2, the Phase 3 pivotal 2L+ trial of monotherapy vepdegestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...